VICO Intrinsic Valuation and Fundamental Analysis - Vicore Pharma Holding AB - Alpha Spread

Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.12 SEK -0.7% Market Closed
Market Cap: 795.5m SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Intrinsic Value

VICO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VICO stock under the Base Case scenario is 7.71 SEK. Compared to the current market price of 7.12 SEK, Vicore Pharma Holding AB is Undervalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VICO Intrinsic Value
7.71 SEK
Undervaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Vicore Pharma Holding AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VICO based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?
How do you feel about VICO?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Vicore Pharma Holding AB

Provide an overview of the primary business activities
of Vicore Pharma Holding AB.

What unique competitive advantages
does Vicore Pharma Holding AB hold over its rivals?

What risks and challenges
does Vicore Pharma Holding AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vicore Pharma Holding AB.

Provide P/S
for Vicore Pharma Holding AB.

Provide P/E
for Vicore Pharma Holding AB.

Provide P/OCF
for Vicore Pharma Holding AB.

Provide P/FCFE
for Vicore Pharma Holding AB.

Provide P/B
for Vicore Pharma Holding AB.

Provide EV/S
for Vicore Pharma Holding AB.

Provide EV/GP
for Vicore Pharma Holding AB.

Provide EV/EBITDA
for Vicore Pharma Holding AB.

Provide EV/EBIT
for Vicore Pharma Holding AB.

Provide EV/OCF
for Vicore Pharma Holding AB.

Provide EV/FCFF
for Vicore Pharma Holding AB.

Provide EV/IC
for Vicore Pharma Holding AB.

Show me price targets
for Vicore Pharma Holding AB made by professional analysts.

What are the Revenue projections
for Vicore Pharma Holding AB?

How accurate were the past Revenue estimates
for Vicore Pharma Holding AB?

What are the Net Income projections
for Vicore Pharma Holding AB?

How accurate were the past Net Income estimates
for Vicore Pharma Holding AB?

What are the EPS projections
for Vicore Pharma Holding AB?

How accurate were the past EPS estimates
for Vicore Pharma Holding AB?

What are the EBIT projections
for Vicore Pharma Holding AB?

How accurate were the past EBIT estimates
for Vicore Pharma Holding AB?

Compare the revenue forecasts
for Vicore Pharma Holding AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vicore Pharma Holding AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vicore Pharma Holding AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vicore Pharma Holding AB compared to its peers.

Compare the P/E ratios
of Vicore Pharma Holding AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Vicore Pharma Holding AB with its peers.

Analyze the financial leverage
of Vicore Pharma Holding AB compared to its main competitors.

Show all profitability ratios
for Vicore Pharma Holding AB.

Provide ROE
for Vicore Pharma Holding AB.

Provide ROA
for Vicore Pharma Holding AB.

Provide ROIC
for Vicore Pharma Holding AB.

Provide ROCE
for Vicore Pharma Holding AB.

Provide Gross Margin
for Vicore Pharma Holding AB.

Provide Operating Margin
for Vicore Pharma Holding AB.

Provide Net Margin
for Vicore Pharma Holding AB.

Provide FCF Margin
for Vicore Pharma Holding AB.

Show all solvency ratios
for Vicore Pharma Holding AB.

Provide D/E Ratio
for Vicore Pharma Holding AB.

Provide D/A Ratio
for Vicore Pharma Holding AB.

Provide Interest Coverage Ratio
for Vicore Pharma Holding AB.

Provide Altman Z-Score Ratio
for Vicore Pharma Holding AB.

Provide Quick Ratio
for Vicore Pharma Holding AB.

Provide Current Ratio
for Vicore Pharma Holding AB.

Provide Cash Ratio
for Vicore Pharma Holding AB.

What is the historical Revenue growth
over the last 5 years for Vicore Pharma Holding AB?

What is the historical Net Income growth
over the last 5 years for Vicore Pharma Holding AB?

What is the current Free Cash Flow
of Vicore Pharma Holding AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vicore Pharma Holding AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vicore Pharma Holding AB

Current Assets 478.2m
Cash & Short-Term Investments 466.4m
Receivables 1.6m
Other Current Assets 10.1m
Non-Current Assets 565k
PP&E 10k
Intangibles 555k
Current Liabilities 39.9m
Accounts Payable 18.2m
Accrued Liabilities 17.1m
Other Current Liabilities 4.7m
Non-Current Liabilities 3.8m
Other Non-Current Liabilities 3.8m
Efficiency

Earnings Waterfall
Vicore Pharma Holding AB

Revenue
104.2m SEK
Operating Expenses
-329.8m SEK
Operating Income
-225.6m SEK
Other Expenses
25.5m SEK
Net Income
-200.1m SEK

Free Cash Flow Analysis
Vicore Pharma Holding AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VICO Profitability Score
Profitability Due Diligence

Vicore Pharma Holding AB's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

17/100
Profitability
Score

Vicore Pharma Holding AB's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

VICO Solvency Score
Solvency Due Diligence

Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VICO Price Targets Summary
Vicore Pharma Holding AB

Wall Street analysts forecast VICO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VICO is 51 SEK with a low forecast of 40.4 SEK and a high forecast of 73.5 SEK.

Lowest
Price Target
40.4 SEK
467% Upside
Average
Price Target
51 SEK
616% Upside
Highest
Price Target
73.5 SEK
932% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VICO?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for VICO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about VICO dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

VICO Price
Vicore Pharma Holding AB

1M 1M
-57%
6M 6M
-55%
1Y 1Y
-56%
3Y 3Y
-65%
5Y 5Y
-61%
10Y 10Y
+37%
Annual Price Range
7.12
52w Low
6.9665
52w High
23.3
Price Metrics
Average Annual Return 13.84%
Standard Deviation of Annual Returns 68.76%
Max Drawdown -81%
Shares Statistics
Market Capitalization 795.5m SEK
Shares Outstanding 111 734 000
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB

Country

Sweden

Industry

Biotechnology

Market Cap

795.5m SEK

Dividend Yield

0%

Description

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

Contact

VASTRA GOTALANDS
Goeteborg
Kronhusgatan 11
+46317880560
vicorepharma.com

IPO

2015-12-10

Employees

23

Officers

See Also

Discover More
What is the Intrinsic Value of one VICO stock?

The intrinsic value of one VICO stock under the Base Case scenario is 7.71 SEK.

Is VICO stock undervalued or overvalued?

Compared to the current market price of 7.12 SEK, Vicore Pharma Holding AB is Undervalued by 8%.

Back to Top